News Akeso and CStone secure China clearances for next-generation... Hong Kong biopharma company Akeso has secured clinical trial clearance in China for a next-generation antibody-drug conjugate (ADC) targeting B7-H3.
News Akiram, ITM sign Lutetium-177 supply agreement Akiram & ITM sign supply agreement for Lutetium-177 to support development of targeted antibody-radionuclide conjugate AKIR001 in solid tumours.
Oncology Sponsored Establishing ctDNA as a validated primary surrogate endpoint Circulating tumour DNA (ctDNA) has emerged as a promising primary surrogate endpoint in solid tumour oncology.
Oncology CAR-NK cell therapies for solid tumours: Closing the gap bet... CAR-NK cell therapies are frequently misunderstood, despite growing clinical and preclinical data supporting their potential.
Oncology Delving into the physics of cancer, with Lew Bender In a new podcast, Intensity Therapeutics' Lew Bender discusses intra-tumourally injected therapeutics - a novel approach to cancer cell death.
Oncology The mesenchymal stem cell’s superpower: Hacking the TME What if we could reprogramme the TME itself? Cutting-edge research suggests that engineered mesenchymal stem cells (MSCs) could disrupt this shield.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.